Figure 6.

 Genistein (GEN) synergizes with arsenic trioxide (ATO) to suppress HepG2 tumors in mice. When tumors reached ∼100 mm³ in volume, the mice received daily injections of 100 μL PBS (Control), or an equal volume of genistein at a dose of 50 mg/kg (GEN), ATO at doses of 2.5 (2.5ATO) or 5 (5ATO) mg/kg, or the combination of genistein + 2.5 mg/kg ATO (2.5ATO + GEN), for 15 days as indicated. (A) The sizes of tumors were recorded. *Significant difference in tumor volumes from control; **highly significant difference from control at P < 0.001; †significant difference from 2.5 mg/kg ATO; ‡significant difference from genistein. Blood samples were collected when the mice were euthanized on day 18, and tumors were removed. (B) The carcasses without tumors were weighed, and compared to the bodyweights on day 0 to calculate bodyweight change (%), and white blood cell (WBC) numbers were counted. (C) The serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT), and (D) urea nitrogen (BUN) and creatinine (Cr) were measured. *Significant difference from control.